LUNGevity’s Career Development Award Program was created to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Research that will be funded in 2021 is expected to have a direct impact on the early detection of lung cancer and/or individualized lung cancer treatment, including through targeted therapy and immunotherapy.
Learn more

The LUNGevity Foundation has announced that Letters of Intent for 2021 research funding opportunities are due February 24, 2021.

LUNGevity’s Early Detection Award Program supports the development of strategies for the early detection and/or diagnosis of lung cancer. Research that will be funded in 2021 is expected to have a direct impact on the early detection and/or diagnosis of lung cancer or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or diagnosis of lung cancer.
Learn more

The LUNGevity Foundation has announced that Letters of Intent for 2021 research funding opportunities are due February 24, 2021.

LUNGevity’s Veterans Affairs Research Scholar Award Program supports fellows or junior faculty interested in lung cancer research within the Department of Veterans Affairs. Projects that will be funded in 2021 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment. In addition, the proposed research must have relevance to the veteran population, related to either screening/early detection of lung cancer or treatment. This is a mentored award.
Learn more

The LUNGevity Foundation has announced that Letters of Intent for 2021 research funding opportunities are due February 24, 2021.

LUNGevity’s Health Equity and Inclusiveness Junior Investigator Award Program supports physician-scientists interested in conducting lung cancer clinical research and bridging health disparities by engaging underserved communities or underrepresented minorities. Projects that will be funded in 2021 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment.
Learn more

The LUNGevity Foundation has announced that Letters of Intent for 2021 research funding opportunities are due February 24, 2021.

LUNGevity’s Health Equity and Inclusiveness Research Fellow Award Program supports fellows interested in translational lung cancer research who belong to underrepresented minorities in STEM. Projects that will be funded in 2021 are expected to have a direct impact on the early detection of lung cancer or on the outcomes of lung cancer, or to provide a clear conceptual or experimental foundation for the future development of methods for early detection and/or individualized treatment. This is a mentored award.
Learn more

The LUNGevity Foundation has announced that Letters of Intent for 2021 research funding opportunities are due February 24, 2021.

Department of Defense Ovarian Cancer Research Program -

Investigator-Initiated Research Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

Partnering PI Option: 
Up to two investigators may collaborate on a single application, each of whom will be recognized as a Principal Investigator (PI) and receive a separate award. 

• Supports meritorious basic and clinically oriented research in ovarian cancer.
• Impact is an important review criterion.
• Preliminary data are required.
• Clinical trials are not allowed. 

Pre-application is required; application submission is by invitation only.

• Maximum funding of $600,000 for direct costs (plus indirect costs).
• Maximum funding of $800,000 for direct costs (plus indirect costs) for Partnering PI Option.
• Maximum period of performance is 4 years.

Pre-application due April 1, 2021

Ovarian Cancer Academy Award – Early-Career Investigator

Must be within 5 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline.

A statement of eligibility is required.

• Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
• Early-Career Investigators whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
• A Designated Mentor may only mentor one Early-Career Investigator.
• The Designated Mentor is not required to be at the same institution as the Early-Career Investigator.
• Preliminary data are required.
• Clinical trials are allowed.
• Pre-application is required; application submission is by invitation only.
• Maximum funding of $725,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years.
• Pre-application due April 1, 2021

Pilot Award

Investigators at or above the postdoctoral level (or equivalent).

• Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
• Innovation and Impact are important review criteria.
• Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.
• Clinical trials are not allowed.
• Pre-application is required and blinded; application submission is by invitation only.
• Maximum funding of $250,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years.
• Pre-application is Due April 1, 2021

Clinical Translational Research Award

Must be an independent investigator at or above the level of Assistant Professor (or equivalent).

• Supports translational research addressing high-impact or unmet needs in ovarian cancer.
• Supports correlative studies related to or associated with planned, ongoing, or completed clinical trials supported by other funding sources. 
• Emphasis on the utilization of precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomes.
• Preliminary data are required.
• Clinical trials are not allowed.
• Pre-application is required; application submission is by invitation only.

• Maximum funding of $450,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.
• Pre-application Due April 1, 2021

Proteogenomics Research Award

Must be at or above the level of postdoctoral fellow (or equivalent).

• Supports the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.
• Innovation and impact are important review criteria.
• Analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged.
• Clinical trials are not allowed.
• Preliminary data are not required but are allowed.
• Submission of a Letter of Intent is required prior to full application submission.

• Maximum funding of $250,000 for direct costs (plus indirect costs).
• Maximum period of performance is 2 years.
• Pre-application due April 1, 2021

Department of Defense Lung Cancer Research Program - Concept Award

All investigators at or above the level of postdoctoral fellow (or equivalent)

• Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.
• Emphasis on innovative concept or untested theory.
• Research involving human subjects or specimens must be either exempt under Title 32, Code of Federal Regulations (CFR), Part 219, Section 104(d)(32 CFR 219.104[d]) or eligible for expedited review (21 CFR 56.110).
• Clinical trials not allowed.

• Preliminary data discouraged (not consistent with intent of award mechanism).
• Military relevance strongly encouraged.
• Maximum funding of $100,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 1 year.
• Letter of Intent Due April 6, 2021

• Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment (or equivalent)
• Most not have received a Career Development Award previously from any program within the Congressionally Directed Medical Research Programs.
• Must not have received more than $300,000 in total direct costs for previous or concurrent lung cancer research as a PI of one or more federally or privately funded, non-mentored, peer-reviewed grants.

Mentor:  At or above the level of Associate Professor (or equivalent),

Must have a strong publication and funding record in lung cancer research

• Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
• Emphasis on research with high potential impact.
• Clinical trials not allowed.
• Career development plan is required with appropriate mentor guidance.
• Preliminary data not required.
• Military relevance strongly encouraged.
• Maximum funding of $250,000 in direct costs (plus indirect costs).
• Period of performance should not exceed 2 years.

The Prostate Cancer Foundation (PCF) & Pfizer, Inc. - PCF-Pfizer Health Equity Challenge Awards

Pfizer Inc. and the Prostate Cancer Foundation (PCF) are proud to announce the PCF-Pfizer Health Equity Challenge Awards, a competitive, peer-reviewed Independent Research grants program for investigators across the globe.
The intent of this program is to support general research projects that will improve the understanding of or reduce disparities in the diagnosis, management, and outcomes of prostate cancer patients in minority and underserved communities.

Composed of a team of at least three (3) investigators, including one young investigator. Applicant (Principal Investigator; PI) must have a medical or doctoral degree (MD, PhD, ScD or equivalent), an advanced nursing degree (BSN with a MS/PhD), MPH or an advanced degree in Pharmacy, Psychology, Psychiatry, Sociology, Physiotherapy, or Social Work with an expertise in public health disparities relative to prostate cancer.
The young investigator may hold the title of Postdoctoral Fellow, Instructor, Research Associate, Assistant Professor, or equivalent and should be within six-years following completion of a professional degree (see above) or subsequent mentored academic or clinical training program.
Applicants must be from non-profit/academic research centers.
Both early career and experienced investigators are encouraged to apply, and consideration will be given to all proposals meeting the selection criteria.
Efforts to increase representation of diverse populations within the investigator team(s) and those designing research projects that are participatory and collaborative [inclusion of voices within the communities most impacted by disparities] are encouraged.

Monetary Range of Grant Awards

• Expected individual grant amounts are in the range of $100K to $150K.
• Approximately $1.5 million USD are allocated to this RFP.
• Applications will be reviewed by an expert review panel (ERP) led by PCF.
• The amount of the grant Pfizer will be prepared to fund for any project will depend upon the expert review panel’s evaluation of the proposal and costs involved, and will be stated clearly in the grant agreement.

View and Download RFP

Letter of Intent (LOI) due date: April 9, 2021

Deadline: June 09, 2021